www.fdanews.com/articles/198295-redhill-biopharma-starts-global-trial-of-yeliva-for-covid-19
RedHill Biopharma Starts Global Trial of Yeliva for COVID-19
July 31, 2020
Redhill Biopharma has launched a global phase 2/3 trial of its Yeliva (opaganib) for treatment of hospitalized COVID-19 patients with pneumonia requiring supplemental oxygen.
The trial will enroll 270 patients to find the proportion of patients requiring intubation and mechanical ventilation by day 14.
Participants will receive Yeliva or a placebo along with the standard-of-care.